Eric J. Loumeau - 30 Sep 2025 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
CHIEF LEGAL OFFICER
Signature
/s/ Eric Loumeau
Issuer symbol
ANAB
Transactions as of
30 Sep 2025
Net transactions value
-$168,860
Form type
4
Filing time
01 Oct 2025, 16:00:20 UTC
Previous filing
07 Jan 2025
Next filing
18 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LOUMEAU ERIC J CHIEF LEGAL OFFICER C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO /s/ Eric Loumeau 01 Oct 2025 0001239648

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $70,100 +5,000 +41% $14.02 17,328 30 Sep 2025 Direct F1
transaction ANAB Common Stock Sale $238,960 -8,240 -48% $29.00 9,088 30 Sep 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -5,000 -6.8% $0.000000 68,000 30 Sep 2025 Common Stock 5,000 $14.02 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes the acquisition of 1,325 shares acquired under the Company's ESPP.
F2 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
F3 The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F4 In addition to the remaining options to purchase 68,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 422,310 shares of common stock, which options vest according to their terms.